Leukemia CML – Blast Crisis

What CML – Blast Crisis Means

>30% blasts; extramedullary disease; acute transformation

Treatment Approach for CML – Blast Crisis

Induction chemotherapy + TKI + urgent HSCT; ponatinib for T315I mutations

Survival Rates and Prognosis

The 5-year survival rate for leukemia at CML – Blast Crisis is approximately 3-6 months without HSCT. Survival rates are statistical averages drawn from large patient populations and may not reflect your individual outcome. Factors that influence your specific prognosis include your age, overall health, tumour biology, and how well the cancer responds to treatment.

Important: These numbers are drawn from historical data. Newer treatments available today may improve outcomes beyond what published statistics show. Discuss your individual prognosis with your oncologist.

How Other Stages Compare

Stage	5-Year Survival	Treatment
ALL – Low Risk	80-90% 5-year event-free survival	Standard induction + consolidation + maintenance (2.5-3 years); CNS prophylaxis…
ALL – High Risk	40-60% 5-year event-free survival	Intensified chemotherapy + TKI (if BCR-ABL+) + consideration of allogeneic HSCT
AML – Favorable	70-80% 5-year overall survival	7+3 induction ± high-dose cytarabine; ATRA + arsenic for APL; selective HSCT…
AML – Intermediate	40-60% 5-year overall survival	7+3 or lower-intensity induction based on age/fitness; standard post-remission…
AML – Unfavorable	5-20% 5-year overall survival	Consider lower-intensity chemotherapy, hypomethylating agents (azacitidine), or…
CML – Chronic Phase	>20 years with TKI monotherapy	First-line TKI (imatinib 400mg, dasatinib 100mg, or nilotinib 300mg daily);…
CML – Accelerated Phase	2-3 years median	Second or third-line TKI; early HSCT consideration; close MRD monitoring
CLL – Rai Stage 0	8-10 years median	Watch-and-wait; defer therapy until symptomatic progression
CLL – Rai Stage III-IV	2-5 years without therapy	Chemoimmunotherapy (rituximab + fludarabine) or venetoclax-based regimens;…